<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/360a–2" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/360a–2/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/360a–2/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_360a_2"><akn:num>360a–2</akn:num><akn:heading>Susceptibility test interpretive criteria for microorganisms</akn:heading><akn:content><akn:p>§ 360a–2. Susceptibility test interpretive criteria for microorganisms(a) Purpose; identification of criteria(1) PurposeThe purpose of this section is to clarify the Secretary’s authority to—(A) efficiently update susceptibility test interpretive criteria for antimicrobial drugs when necessary for public health, due to, among other things, the constant evolution of microorganisms that leads to the development of resistance to drugs that have been effective in decreasing morbidity and mortality for patients, which warrants unique management of antimicrobial drugs that is inappropriate for most other drugs in order to delay or prevent the development of further resistance to existing therapies;

(B) provide for public notice of the availability of recognized interpretive criteria and interpretive criteria standards; and

(C) clear under section 360(k) of this title, classify under section 360c(f)(2) of this title, or approve under section 360e of this title, antimicrobial susceptibility testing devices utilizing updated, recognized susceptibility test interpretive criteria to characterize the in vitro susceptibility of particular bacteria, fungi, or other microorganisms, as applicable, to antimicrobial drugs.


(2) Identification of criteriaThe Secretary shall identify appropriate susceptibility test interpretive criteria with respect to antimicrobial drugs—(A) if such criteria are available on the date of approval of the drug under section 355 of this title or licensure of the drug under section 262 of title 42 (as applicable), upon such approval or licensure; or

(B) if such criteria are unavailable on such date, on the date on which such criteria are available for such drug.


(3) Bases for initial identificationThe Secretary shall identify appropriate susceptibility test interpretive criteria under paragraph (2), based on the Secretary’s review of, to the extent available and relevant—(A) preclinical and clinical data, including pharmacokinetic, pharmacodynamic, a</akn:p></akn:content><akn:subsection eId="subsec_360a_2_a"><akn:num>(a)</akn:num><akn:heading>Purpose; identification of criteria</akn:heading><akn:content><akn:p>(a) Purpose; identification of criteria</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360a_2_b"><akn:num>(b)</akn:num><akn:heading>Susceptibility test Interpretive Criteria Website</akn:heading><akn:content><akn:p>(b) Susceptibility test Interpretive Criteria Website</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360a_2_c"><akn:num>(c)</akn:num><akn:heading>Recognition of susceptibility test interpretive criteria</akn:heading><akn:content><akn:p>(c) Recognition of susceptibility test interpretive criteria</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360a_2_d"><akn:num>(d)</akn:num><akn:heading>Antimicrobial drug labeling</akn:heading><akn:content><akn:p>(d) Antimicrobial drug labeling</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360a_2_e"><akn:num>(e)</akn:num><akn:heading>Special condition for marketing of antimicrobial susceptibility testing devices</akn:heading><akn:content><akn:p>(e) Special condition for marketing of antimicrobial susceptibility testing devices</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360a_2_f"><akn:num>(f)</akn:num><akn:heading>Definitions</akn:heading><akn:content><akn:p>(f) Definitions In this section:</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360a_2_g"><akn:num>(g)</akn:num><akn:heading>Rule of construction</akn:heading><akn:content><akn:p>(g) Rule of construction Nothing in this section shall be construed to—</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>